

Text for Supplementary Table 1

Evaluation of the expression of cyclin A1, VEGF, MMP2 and MMP9 in benign prostate and adjacent prostate cancer specimens. Specimens from 482 patients with prostate cancer were used. Selected areas of prostate cancer and corresponding benign samples were subjected in duplicates to tissue microarray constructs of 1.0 mm in diameter. Block 1(a) and Block 1(b) indicate prostate cancer samples. Block 2(a) and Block 2(b) indicate adjacent benign prostate sample. Tumor Gleason grade for cancer and clinical features such as stromal inflammation for benign tumors were evaluated by two independent pathologists and were therefore listed in duplicates. Expression of cyclin A1 (a1), VEGF, MMP2 and MMP9 were evaluated and the staining intensity were scored by three independent scientists following the standard scoring system: 0 (negative), 1 (weakly positive or positive), 2 (moderate positive), 3 (strongly positive) and 4 (very strongly positive). The empty space indicates that the samples are missing in TMA blocks.

Supplementary Table 2

Correlation between cyclin A1, VEGF, MMP2 and MMP9 expression in 482 patients with prostate cancer.

	Cyclin A1		VEGF		MMP9		MMP2	
	Low	High	Low	High	Low	High	Low	High
	109	331	206	228	310	117	319	85
	24.77 %	75.23%	47.46 %	52.54%	72.60%	27.40%	78.96%	21.04%
Cyclin A1	-		0.656**		0.432**		0.123**	
VEGF	0.656**		-		0.366**		0.179**	
MMP9	0.432**		0.366**		-		0.05	
MMP2	0.123**		0.179**		0.05		-	

Spearman's rho values are given in the table. ** indicates the correlation significance at the 0.01 level (two-sided).

Supplementary Table 3

Correlation between cyclin A1 and AR expression in 99 patients with Gleason grade above 4.

AR expression	<u>Cyclin A1 expression in patients</u>	
	<u>Cytoplasmic</u>	<u>Nuclear</u>
Low group	% (number) 65.4% (17)	% (number) 34.6% (12)
High group	34.6% (9)	83.6% (61)